logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
PE/Texas Red® Anti-human CD3 Antibody
OKT-3
OKT-3 is an anti-human monoclonal antibody that targets the CD3e antigen. CD3e (alternatively called T cell antigen receptor complex or TCRE) is a 20 kD member of the Ig superfamily that is located on the surface of cells like T cells. CD3 is a member of important cellular pathways, in particular, the cell surface receptor signaling pathway, T cell receptor signaling pathway and negative regulation of smoothened signaling pathway. Furthermore, in certain organisms, it positively regulates calcium-mediated signaling, upregulates peptidyl-tyrosine phosphorylation and enhances cell-matrix adhesion. From a research standpoint, it is of biological interest due to its association with vital macromolecules/ligands such as TCR. CD3 is a very popular antibody target, with over 80000 publications in the last decade. CD3e is vital to immunology research, typically serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to PE/Texas Red® (ex/em = 567/615 nm). It is compatible with the 561 nm laser and 610/20 nm bandpass filter (for example, as in the BD FACSJazz™).
product image
product image
CatalogSize
Price
Quantity
100341S025 tests
Price
100341S1100 tests
Price
100341S2500 tests
Price
 
Antibody properties

Other namesT3E
CloneOKT-3
Hostmouse
Isotypemouse igg2a, κ
Reactivityhuman
Spectral properties

Extinction coefficient (cm -1 M -1)
1960000
Excitation (nm)565
Emission (nm)613
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on November 5, 2025